During the Zhongshan Medical Retina and Epidemiology Symposium, I was honored to meet Dr. Chew and invite her for a brief interview to share his expertise on AREDS. At the beginning of the interview, Dr. Chew briefly introduced her present a tion on AREDS 2 in the symposium, mainly talking about the primary outcome of testing the effect of lutein/zeaxanthin and omega-3 for macular degeneration treatment. She also shared with us that lutein and zeaxanthin, rather than omega-3 are important for the treatment. Dr. Chew claimed that one of the biggest challenges in the study was that they had to make sure that all the elderly patients come back and to raise money to support their study. In the interview, Dr. Chew also mentioned a large clinical trial she involved called the ACCORD; she emphasized the importance of tight blood sugar control for the decrease of diabetic retinopathy. When asked about the greatest accomplishment in her career, Dr. Chew replied that she hoped that she still had more things to do, like training young ophthalmologists and helping them to succeed.